A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_7A92BC1E6EB4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
UNIL/CHUV
Titre
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Périodique
Clinical lung cancer
Auteur⸱e⸱s
Garon E.B., Cho B.C., Luft A., Alatorre-Alexander J., Geater S.L., Trukhin D., Kim S.W., Ursol G., Hussein M., Lim F.L., Yang C.T., Araujo L.H., Saito H., Reinmuth N., Kohlmann M., Lowery C., Mann H., Peters S., Mok T.S., Johnson M.L.
ISSN
1938-0690 (Electronic)
ISSN-L
1525-7304
Statut éditorial
In Press
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Mots-clé
Clinical trial, Cytotoxic T-lymphocyte-associated antigen 4, Immune checkpoint inhibitor, Immunotherapy, Programmed cell death ligand-1
OAI-PMH
oai:serval.unil.ch:BIB_7A92BC1E6EB4
DOI
10.1016/j.cllc.2024.03.003
Pubmed
38584069
Open Access
Oui
Création de la notice
12/04/2024 9:16
Dernière modification de la notice
13/04/2024 7:06
Données d'usage